Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
NR283 Pathophysiology RUA: Pathophysiological Processes Guidelines NR283 Pathophysiological Processes Guidelines V4.docx Revised: 05/2018 11 Purpose This project is an in depth inv
NR283 Pathophysiology RUA: Pathophysiological Processes Guidelines NR283 Pathophysiological Processes Guidelines V4.docx Revised: 05/2018 11 Purpose This project is an in depth investigation of a health condition. It will allow for the expansion of knowledge and the ability to generalize larger concepts to a variety of health conditions. Course outcomes: This assignment enables the student to meet the following course outcomes: 1. Explain the pathophysiologic processes of select health conditions. (PO 1) 2. Predict clinical manifestations and complications of select disease processes. (PO 1, 8) 3. Correlate lifestyle, environmental, and other influences with changes in levels of wellness. (PO 1, 7) Due date: Your faculty member will inform you when this assignment is due. The Late Assignment Policy applies to this assignment. Total points possible: 100 points Preparing the assignment Follow these guidelines when completing this assignment. Speak with your faculty member if you have questions. 1) Select a disease process that interests you. 2) Obtain approval of the selected disease process from the course faculty. a. Faculty will share how to submit your topic choice for approval. 3) Write a 2‐3 page paper (excluding title and reference pages). 4) Include the following sections about the selected disease process (detailed criteria listed below and in the Grading Rubric). a. Introduction of disease ‐ 20 points/20% • One paragraph (approximately 200 words) • Includes disease description • Includes epidemiology of disease b. Etiology and risk factors ‐ 20 points/20% • Common causes of the disease or condition • Risk factors for the disease or condition • Impact of age • Prevalence based on gender, • Influence of environment • Genetic basis of disease • Lifestyle influences • All information supported by current literature c. Pathophysiological processes ‐ 20 points/20% • Describes changes occurring at the cellular, tissue, and/or organ level that contribute to the disease process. • Describes adaptation of the cells and body in response to the disease. • Relates disease processes to manifested signs and symptoms. d. Clinical manifestations and complications ‐ 20 points/20% • Describes the physical signs and symptoms that are important in considering the presence of the disease. • Identifies signs that contribute to diagnosis of the condition • Identifies symptoms that contribute to diagnosis of the condition. • Identifies complications of the disease. • Discusses the implications to the patient when complications are left untreated. e. Diagnostics ‐ 10 points/10% • Includes list of common laboratory and diagnostic tests used to determine the presence of the disease. 2 NR283 Pathophysiology RUA: Pathophysiological Processes Guidelines NR283 Pathophysiological Processes Guidelines V4.docx Revised: 05/2018 21 • Discusses the significance of test findings in relation to the disease process. f. APA Style and Organization ‐ 10 points/10% • References are submitted with assignment. • Uses appropriate APA format (6th ed.) and is free of errors. • Grammar and mechanics are free of errors. • Paper is 2‐3 pages, excluding title and reference pages • At least two (2) scholarly, primary sources from the last 5 years, excluding the textbook, are provided For writing assistance (APA, formatting, or grammar) visit the Citation and Writing Assistance: Writing Papers at CU page in the online library.
- @
- ANSWER
-
Tutor has posted answer for $30.00. See answer's preview
************* Introduction *** ************************ is * ******* **** ******** ************* ** ******** ************ ******* ** the **** ********* *** ********* ** *********** ** * primary ******** ******** ********* **** ********* changes ********* to *** **** ** **** ******** ***** ******* ***** ****** ***** *** disorder ******* **** ***************** ******* to progressive **** of **** density and subsequent ********* ******** ********* ** **** ************* et ** ***** Two ******* million ******* across *** world are ********* ** **** osteoporosis **** ******* being ****************** ******** ******** ** ***** whereby **** of ***** and 9-38% of ******* ** the ***** ***** ******* are affected (Sozen ****** & ******* 2017) Caucasians *** the **** ******** race Additionally the ********* ** *** ******* ********* **** *** ***** most ******** *** *** ********* ****** ******* ****** **** *** ******** ** an increasing ******* especially in women *** have experienced ********* *** *** ******* *** ** *** incidence of ********** ********* ** the ****** years ********* have **** demonstrated ** ***** *** to ************ ************* 33% of ******* *** *** ** ***** **** 50 ***** *** having ********** ********* are ****** ** ************ ****** ***** *** ********* ** ************ being viewed ** a ****** ******** in **** ** *** ********* ******** and *** number of ********** ******** the ***** ** ************ ** ** (2018) *** ** that *** ********** ********* set * ******* of ********** decreased quality ** **** ********** ***** *** at worse mortalityb ******** and **** ********** ******** ** ************ is ******* The disorder ** ********** **** ******* *** ********* ***** (Akkawi ***** ****** ***** *** ******* ******* which ***** * correlation to aging and sex-hormone ************ has *** subcategories **** 1 ***************** *** **** II ******** osteoporosis ****** Clark ***** Sandhu ***** ********* osteoporosis ******* **** ***** ****** ****** atrophy ******************* ********** such ** glucocorticoids ******* ***** ******* ** **** malabsorptive ********* ******* ***** Zmerly ***** *** develop ********* ************ more ******** **** ******* *** predisposing factors *** osteoporosis ******* ********* *** ****** history ***** **** weight ***** **** ***** ****** predilection ******* *** ********* ********** *** calcium diet as **** as alcohol *********** *** **** **** ******** *************** *** *************** *********** ** bone tissue ****** on ****** ** ********** ******** *** ********** ************* *** ******* ********* ** *** ********** *** progress ** osteoporosis ** ** ********* between **** ********** *** ********** ******* & LeBoff 2018) ******* ******* enhance ** ********* ************ ******** ** **** over ************ ******** ************ the **** ******** and ***** reducing *** ******* **** ********** exceeds ********** *** density of bone is lost ******* *********** ******** ** *** microarchitecture *** ********** ****** ******* to increased ********* (Tu et al ***** Later *** ********* ** *** condition ** announced by ************ ********* Nevertheless ** **** *********** ** ******** ********* their failure to reach **** bone **** ***** *** that also *********** the ************ ******* *** ** ** ***** ******** ********* ******* ********* *** ****** all ****** PBMd ClinicalManifestationsandComplicationThe **** ************** ******* ** ************ is * ******** Usually *** ******* ** ****** ** that ***** **** that unexplained ********* in ***** ****** should ***** ********* *** fracture ****** ** the vertebrae *** ***** and ******** *** ** ** 2018) ***** ** ****** ********* pain ********* *** ******** immobility **** ***** are the ************* ** the ******** **** ******* ******** ** ********* *************** **** ** ****** thrombosis ********* ****** *** ********** ********* ****** Ozisik ***** ******* ***** The ********* **** **** ****** ********** ****** isolation increased ********** ***** *** ******* ******* ** **** Failure ** ***** ************* *** **** ** ***** *** ********* ********* cause ********* DiagnosticsThe ********* is definitively **** ***** **** ******* densitometry ***** ***** ******* dual-energy X-ray ************** ****** ***** ***** ****** 2014) *** ********* ******* *** ****** of ******* with deviations **** mean *** values used It is ***** ****** that *********** the ****** ** ************ ******** ***** * raft ** ***** to **** *** ***** ********* ****** *** ***** include *** UECS *** vitamin D levels *** ***** protein *************** (SPEP) *** hormonal ***** ****** Clark ***** ****** ***** *** ****** ****** **** ********** calcium ****** ** ***** and **** to **** out ******** ******* Other ******* ********** can ** employed as **** ** *** earlier testing *** ** ***** ****** ****************************************** * ***** Zmerly H (2018) ************* Current ******** ****** **** ******* Retrieved **** ****************************************************** * * ****** B * & ****** * * ****** Osteoporosis ********** ********* *** treatment: * review ******* ** ******* ****** ***** ******* ********* from https://wwwncbinlmnihgov/pmc/articles/PMC4089021/Pouresmaeili * ************* * ********* M ***** *** * * ****** * ************* ******** ** ************ *** *** risk ******* ************ and ******** **** ********** ** ***** ********* **** ****************************************************** * J ****** *** ************ *** pathogenesis of ************ ********* *** ********* **** *********************************************** * ********** L ***** ******** * Ç (2017) An ******** *** ********** ** ************ ******** Journal ** Rheumatology 4(1) ** ********* from *************************************************** * * Lie * * *** * * V ******* * ****** A * Nguyen * K ***** **** * (2018) ************* * ****** of ********* ******* Pharmacy *** ************ 43(2) ** ********* **** https://wwwncbinlmnihgov/pmc/articles/PMC5768298/Zaheer * ***** ****** M S ****** ************* ********** *** treatment ********* *** Retrieved **** ******************************************************** ************ and ************************ is a ******* bone ******** ************* ** ******** pathological ******* ** the **** ********* *** ********* ** *********** ** * ******* skeletal ******** resulting from metabolic ******* localized ** *** **** ** **** ******** cause ******* ***** ****** ***** *** disorder ******* bone microarchitecture leading to *********** **** ** bone ******* and subsequent ********* ******** ********* ** **** ************* ** ** 2018) *** ******* ******* persons ****** *** world are ********* ** **** ************ **** females being ****************** ******** ******** to ***** whereby 2-8% ** ***** *** ***** of females ** *** ***** world ******* are ******** ****** Ozisik ***** Basaran ***** ********** are *** **** ******** **** ************ *** incidence ** *** ******* ********* **** *** since most ******** *** the agedRosen ****** further ****** **** the ******** ** an ********** ******* ********** ** ***** *** have *********** menopause *** *** elderly *** ** *** incidence ** ********** ********* ** *** ****** years fractures **** been ************ ** arise *** to osteoporosis ************* *** of ******* *** *** of ***** over ** ***** *** ****** ********** fractures are ****** ** ************ ****** ***** *** condition ** ************ ***** ****** as a global ******** in **** ** *** increased ******** and *** ****** ** geriatrics ******** *** ***** ** ************ et al ****** *** ** **** *** pathologic fractures set * cascade ** disability decreased quality of life ********** ***** and ** worse ********** ******** *** Risk ********** ******** of ************ is ******* *** ******** ** ********** into primary and secondary ***** (Akkawi ***** ****** ***** The ******* ******* which ***** * *********** ** aging *** *********** ************ has *** ************* **** * ***************** *** type ** (senile) ************ ****** ***** ***** ****** ***** ********* ************ results **** ***** ****** disuse atrophy ******************* ********** such ** *************** chronic ***** ******* ** even ************* disorders ******* ***** ****** 2018) *** ******* ********* osteoporosis more ******** **** ******* *** predisposing ******* *** ************ include ********* age ****** ******* ***** **** ****** (less **** ***** ****** ************ smoking *** prolonged ********** *** calcium **** ** well ** ******* *********** are **** **** factorsc *************** *** *************** *********** ** bone ****** ****** ** ****** ** ********** ******** *** ********** ************* *** primary ********* ** *** ********** *** ******** ** ************ ** ** ********* ******* **** ********** *** remodeling ******* ***** ****** 2018) Various ******* enhance ** ********* ************ ******** ** **** **** ************ ******** ************ *** **** ******** *** ***** reducing *** density **** ********** ******* ********** *** density of **** ** lost ******* *********** ******** ** *** ***************** and ********** ****** leading ** ********* ********* *** et ** ***** ***** the ********* ** *** condition is ********* ** ************ ********* ************ ** some *********** it ******** ********* ***** ******* ** ***** **** bone **** ***** *** **** **** accelerates *** ************ process *** et ** 2018) ******** ********* factors nutrition *** ****** *** affect PBMd **************************************** **** characteristic ******* ** ************ ** * fracture ******* *** disease is silent ** **** ***** **** **** *********** ********* ** older ****** ****** ***** ********* The fracture ****** ** *** ********* *** ***** *** shoulder *** et al ***** ***** ** ****** attendant pain ********* and ******** ********** **** worse are *** ************* of *** disorder **** ******* problems ** ********* hospitalization **** ** venous thrombosis ********* ****** *** hypostatic pneumonia ****** ****** ***** ******* ***** *** ********* **** **** ****** ********** ****** ********* ********* healthcare ***** and reduced ******* of **** Failure ** ***** ************* *** **** to death *** ********* ********* cause ********* ************** ********* is ************ made ***** **** mineral ************ (BMD) which ******* *********** ***** absorptiometry ****** Clark ***** Sandhu ***** *** ********* ******* *** ****** of ******* **** ********** **** **** *** ****** **** ** ** ***** noting that *********** *** ****** of ************ ******** ***** * **** ** tests ** **** out ***** ********* ****** The tests ******* CBC **** *** ******* * levels *** serum ******* *************** ****** *** ******** ***** ****** Clark ***** Sandhu ***** *** ****** Anemia **** ********** ******* ****** ** ***** and **** ** **** *** ******** ******* ***** imaging ********** *** be ******** as **** ** *** ******* ******* and it ***** ****** osteopenia ReferencesAkkawi * & ****** * (2018) ************* ******* concepts ****** **** 122-127 ********* **** ****************************************************** * * ****** * L ***** Sandhu * * (2014) ************ ********** ********* *** ********** * review Journal of Women's ****** 23(7) ******* Retrieved from https://wwwncbinlmnihgov/pmc/articles/PMC4089021/Pouresmaeili * Kamalidehghan * Kamarehei * ***** *** Y * (2018) * comprehensive ******** ** osteoporosis *** *** **** factors Therapeutics and Clinical Risk ********** 14 20-29 ********* from ****************************************************** * * (2017) *** epidemiology *** pathogenesis ** Osteoporosis ********* *** ********* **** *********************************************** * ********** L ***** Başaran * ** (2017) ** overview *** management ** osteoporosis ******** ******* of ************ **** 46 ********* **** *************************************************** * * *** * * Wan * * V Cameron * ****** A * ****** J * ***** **** D (2018) ************* * review ** treatment options ******** *** ************ 43(2) ** ********* from https://wwwncbinlmnihgov/pmc/articles/PMC5768298/Zaheer S ***** ****** * * (2018) ************* ********** *** ********* ********* Inc Retrieved **** *********************************************
